Information Provided By:
Fly News Breaks for October 11, 2017
Oct 11, 2017 | 15:23 EDT
As previously reported, Cantor Fitzgerald raised Abeona Therapeutics' price target to $34 from $21 following new initial MPS IIIA data from a third patient cohort dosing at a higher and potentially pivotal stage dose of ABO-102. In addition the company expects to initiate a Phase III study in 1H 2018 for its EB-101 program. The analyst increased his probability of success to 60% from 30% for both the MPS IIIA and EB programs and reiterates an Overweight rating on shares.
News For ABEO From the Last 2 Days
There are no results for your query ABEO
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.